Identification of a familial cleidocranial dysplasia with a novel RUNX2 mutation and establishment of patient-derived induced pluripotent stem cells

Odontology. 2022 Jul;110(3):444-451. doi: 10.1007/s10266-021-00674-5. Epub 2021 Nov 15.

Abstract

Cleidocranial dysplasia (CCD) is an autosomal dominant hereditary disease associated with the gene RUNX2. Disease-specific induced pluripotent stem cells (iPSCs) have emerged as a useful resource to further study human hereditary diseases such as CCD. In this study, we identified a novel CCD-specific RUNX2 mutation and established iPSCs with this mutation. Biopsies were obtained from familial CCD patients and mutation analyses were performed through Sanger sequencing and next generation sequencing. CCD-specific human iPSCs (CCD-hiPSCs) were established and maintained under completely defined serum, feeder, and integration-free condition using a non-integrating replication-defective Sendai virus vector. We identified the novel mutation RUNX2_c.371C>G and successfully established CCD-hiPSCs. The CCD-hiPSCs inherited the same mutation, possessed pluripotency, and showed the ability to differentiate the three germ layers. We concluded that RUNX2_c.371C>G was likely pathogenic because our results, derived from next generation sequencing, are supported by actual clinical evidence, familial tracing, and genetic data. Thus, we concluded that hiPSCs with a novel CCD-specific RUNX2 mutation are viable as a resource for future studies on CCD.

Keywords: Cleidocranial; Dysplasia; Mutation; RUNX2; iPSC.

MeSH terms

  • Cleidocranial Dysplasia* / genetics
  • Core Binding Factor Alpha 1 Subunit / genetics
  • Humans
  • Induced Pluripotent Stem Cells*
  • Mutation

Substances

  • Core Binding Factor Alpha 1 Subunit
  • RUNX2 protein, human